COMPANY:

Mainz BioMed

"Mainz Biomed...announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercialized across Europe and in select international markets. This advanced version of the Company’s colorectal cancer (CRC) screening test is set to become the standard offering for all existing partners, reflecting its proven benefits in optimizing screening efficiency and improving user experience."

"Mainz Biomed N.V...announced today the expansion of its collaboration with Liquid Biosciences to Mainz Biomed’s next-generation detection test for pancreatic cancer. The companies will leverage Liquid Biosciences proprietary AI analysis technology platform (EMERGE) to expand and optimize the selection of novel biomarkers for PancAlert."

"Mainz Biomed N.V...today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations."

"Mainz Biomed...announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for its non-invasive Next Generation colorectal cancer (CRC) product including the Company’s novel portfolio of mRNA biomarkers. Subject to the FDA’s review, a Breakthrough Device Designation could significantly accelerate approval."

"Mainz Biomed N.V...is excited to announce its participation in the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting....The combined analysis from the ColoFuture and eAArly DETECT studies represents the largest dataset to date, with 690 subjects including previously unexamined and unreported subjects enrolled across 30 clinical sites."

"Mainz Biomed N.V....will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21st. DDW is recognized as a premier forum for the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery....The results show compelling performance of its multimodal screening test combining Fecal Immunochemical Test (FIT), DNA and mRNA biomarkers with a unique artificial intelligence (AI) / machine learning algorithm to differentiate between colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas and patient samples with no findings."

"Mainz Biomed...announced today groundbreaking topline results from a pooled clinical study which included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials evaluating the potential to integrate its portfolio of proprietary novel gene expression (mRNA) biomarkers into a next generation version of the Company’s colorectal cancer (CRC) screening tool."

"Mainz Biomed N.V...is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany. One of the main focus topics for this year’s event, organized by the German Complementary Medicine Association (Union Deutscher Heilpraktiker, Landesverband Baden-Württemberg), is the gut and its significance in the manifestation of diseases....By presenting ColoAlert at the UDH Congress, Mainz Biomed highlights the role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies, demonstrating the synergy between technological innovation and patient-centric care."

"Mainz Biomed N.V...announced today a partnership with Trusted Health Advisors (THA), a market leader in supporting the U.S. launches and management of commercial programs for diagnostic products...In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test...'As we make the final preparations to commence patient enrollment in the ReconAAsense trial and given the potentially transformative role the test will have on the market if approved, we are excited by the opportunity to be in a position to advance our U.S. go-to-market strategy for our innovative approach in CRC screening.'....'Through our partnership with THA, we plan to expedite and enhance the deployment of our differentiated commercial strategy to enable an efficient and impactful transition to the marketplace for the product which if approved, we anticipate will occur in 2026.'"

"Mainz Biomed...s pleased to announce a distribution partnership with Praxisdienst...This collaboration, which commenced in February 2024, marks an important step in Mainz Biomed’s mission to enhance healthcare delivery across Germany, focusing on the accessibility of their flagship product, ColoAlert®."

"Mainz Biomed N.V...announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership signifies a major step forward in enhancing colorectal cancer screening and diagnostics within the Italian healthcare system as it enables the implementation of ColoAlert into Italy's robust healthcare framework, providing patients with access to a cutting-edge diagnostic solution that combines convenience with clinical excellence."

"Mainz Biomed...announces the opening of the ‘European Oncology Lab’ (EOL). The physician-led facility represents an expansion of the Company’s collaboration with Laboratory Dr. Buhlmann with a shared location in Saarland, Germany...Via the EOL, medical professionals or patients can now order ColoAlert® directly with Mainz Biomed as a laboratory medical service, meeting a crucial requirement to invoice private health insurance companies."

"Mainz Biomed N.V...re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024. The companies joined forces to advance innovative colorectal cancer (CRC) detection in Poland and to increase treatment options as well as survival rates through early detection....The 10th Gdańsk Gastroenterology Symposium gathers national Polish lecturers, scientists, and practitioners who will share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy. Mainz Biomed and TestDNA will be present as exhibitor during the two day symposium, they will also open the second day of panel discussions."

"Mainz Biomed N.V. announced a year end summary of its corporate and product development progress...Announced groundbreaking results from ColoFuture (Europe) and eAArly DETECT (U.S.) clinical studies evaluating the potential to integrate portfolio of novel gene expression (mRNA) biomarkers into a next generation version of ColoAlert."

"Mainz Biomed N.V...announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation....The first attended conference, the 17th Conference: Advances in Gastroenterology, ran from December 8th to 9th, 2023, in Poznań....Following this, Mainz Biomed will be taking part in the 10th Gdańsk Gastroenterology Symposium which runs from January 12th to 13th, 2024."

"Mainz Biomed N.V...announced today groundbreaking topline results from its eAArly DETECT U.S. clinical study, a multi-center feasibility study assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into a next generation version of ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. The eAArly DETECT topline results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. They confirm the positive results from ColoFuture, its European counterpart which reported data in October 2023."

"Mainz Biomed NV...announced a strategic partnership with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE) to serve the biopharma and diagnostics industries along with academic institutions."

"Mainz Biomed N.V...announced that VP Commercial Operations, Tarrin Khairi-Taraki, will attend MEDICA by invitation of the Rhineland-Pfalz government."

P=NA | N=NA | "Mainz Biomed N.V...a molecular genetics diagnostic company specializing in the early detection of cancer is presenting its groundbreaking results of its ColoFuture Study....The presented results of the groundbreaking study included a sensitivity for CRC of 94% with a specificity of 97% and a sensitivity for advanced adenoma (AA) of 80%."

"Mainz Biomed NV...announced today its participation in the upcoming UEG Week. This prominent event, organized by the United European Gastroenterology and scheduled to take place in Copenhagen, Denmark, from October 14th to 17th, serves as a premier platform for discussing the latest advancements and breakthroughs in the field of gastroenterology."

"Mainz Biomed NV...announces the live launch of Mainz Biomed’s flagship product, ColoAlert^® — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - with strategic partner Bioclinica, a national leader in the Romanian healthcare sector. This partnership signifies a pivotal step towards enhancing healthcare outcomes in the country through advanced diagnostics....The collaboration with Bioclinica adds significant value to Mainz Biomed's mission."

"Mainz Biomed N.V...announced today that it will present the positive detailed results from its ColoFuture study at the 4th International Conference on Gastroenterology which occurs on October 16th - 18th in Paris, France. The ColoFuture study was a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories."

"Mainz Biomed N.V...announced positive topline results from its ColoFuture study. The ColoFuture study is a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) which is being commercialized across Europe and in select international territories. The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%."

"Mainz Biomed N.V...announced today a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market...The collaboration grants Mainz Biomed greater access to, and the potential for further expansion into Germany’s private health insurance segment where ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC), already receives reimbursement."

"Mainz Biomed NV...announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp. z o. o. Sp. K...The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer ('CRC')."

"Mainz Biomed NV...announced today that London-based Marylebone Laboratory (Marylebone Lab Ltd) has introduced ColoAlert, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) – to its extensive UK and international customer base. Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal cancer (CRC) and save lives through advanced diagnostics."

"Mainz Biomed NV...announces today its commercial partnership for ColoAlert with Fugene Genetics, a renowned genetic testing service provider based in Israel."

"Mainz Biomed NV...announce its participation in the highly anticipated ESMO World Congress on Gastrointestinal Cancer 2023. The event, organized by the European Society for Medical Oncology and held in Barcelona, Spain from June 28th to July 1st, serves as a platform for sharing cutting-edge research and innovations that are revolutionizing the field of gastrointestinal oncology...the companies will showcase ColoAlert, the innovative at-home screening test for CRC by Mainz Biomed."

"Mainz Biomed NV...announce the addition of Bioclinica to its esteemed network of laboratory partners. Bioclinica will play a crucial role in supporting the commercialization efforts of ColoAlert, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer (CRC). This strategic collaboration marks another milestone in Mainz Biomed’s mission to revolutionize the diagnosis and prevention of life-threatening diseases, particularly CRC, which continues to be the second most lethal cancer in Europe."

"Mainz Biomed NV...announced today the establishment of a commercial partnership for ColoAlert with TESTDNA Sp. z o.o. Sp. k. Katowice, Poland, a leading independent laboratory in Poland."

"Mainz Biomed NV...announced today initial results from its colorectal cancer (CRC) screening campaign through its BGM ('betriebliches Gesundheits management') partnership with Zoller -Kipper GmbH, part of the Zoller group with more than 2,500 employees. In April 2023, Zoller -Kipper selected ColoAlert, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program."

"Mainz Biomed N.V...announced today a research collaboration with Microba Life Sciences...As part of the agreement, Microba and Mainz Biomed will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools to potentially discover novel microbiome biomarkers for pancreatic cancer detection."

"Mainz Biomed NV...announced today that it has added Eurofins GeLaMed to its network of lab partners offering PCR test kit processing of ColoAlert, its flagship product that is a highly efficacious and easy to use at-home screening test for colorectal cancer (CRC)."

"Mainz Biomed NV...announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert®, Mainz Biomed’s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC)."

"Mainz Biomed NV...announced today that three German-based companies, have selected ColoAlert, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs."

"Mainz Biomed NV...announced today results of an independent feasibility study conducted in collaboration with members of the Early Detection Research Network (EDRN) to evaluate the Company’s portfolio of five novel gene expression (mRNA) biomarkers acquired from Université de Sherbrooke in January, 2022....In univariate analysis, demonstrated statistically significant differences between: CRC specimens and controls p=0.0002 and p=0.001, respectively and more importantly, Advanced adenoma (AA) specimens and controls p=0.0005 and p=0.07 (trend), respectively...The Company now awaits results from the eAArly DETECT clinical trial which commenced enrollment in December of 2022 and remains on track to report results in mid-year 2023. This multi-center feasibility study is enrolling 250 subjects across 25 sites in the U.S."

"Mainz Biomed NV...announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC)."

"Mainz Biomed N.V...announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ('IP') for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe."

"Mainz Biomed NV...announced today the establishment of commercial partnerships for ColoAlert with Marylebone Laboratory (Marylebone Lab LTD) and Instituto de Microecologia, two leading independent laboratories covering England and Spain."

"Mainz Biomed NV...announced today the launch of a corporate health program in Germany for ColoAlert, its highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories."

"Mainz Biomed NV...announced today the first patient has been enrolled in eAArly DETECT, Mainz’s U.S. extension of ColoFuture, its European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert.Currently, Mainz is commercializing ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) across Europe and in select international territories....Mainz expects to complete enrollment for the eAArly DETECT in Q1 2023 and targets reporting topline results in 1H 2023. Based on the study’s outcome, the Company will determine which of the biomarkers are eligible for inclusion in the Company’s U.S. pivotal trial (ReconAAsense), which is on schedule to begin enrolling patients in 2023 with results expected in 2025."

"Mainz Biomed said Tuesday that it has received approval from an independent institutional review board for the trial protocol of its ReconAAsense study. The study, which will recruit 15,000 individuals across the US, is to evaluate the clinical performance of the firm's colorectal cancer early detection test in order to support a submission for review by the US Food and Drug Administration...Mainz's ColoAlert assay combines analysis of DNA, mRNA, and fecal immunohistochemistry to identify cancer in asymptomatic individuals from a stool sample. The company currently markets the test across Europe and the United Arab Emirates."